DMAC — DiaMedica Therapeutics Share News
0.000.00%
Last trade - 00:00- $513.37m
- $469.88m
DiaMedica Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: TomEnterprise AB Reports 9.6% Passive Stake In DiaMedica Therapeutics
Brief: Diamedica Therapeutics Inc Files For Offering Of Up To 7.65 Million Common Shares By The Selling Shareholders - SEC Filing
DiaMedica rises on FDA fast track tag for stroke therapy
Brief: DiaMedica Therapeutics Announces Fast Track Designation Granted to DM199 for the Treatment of Acute Ischemic Stroke
Brief: Diamedica Therapeutics Closes $30 Mln Private Placement
Brief: Diamedica Therapeutics Announces $30 Mln Private Placement
Brief: DiaMedica Initiates Pivotal Trial Of DM199 For Treatment Of Acute Ischemic Stroke
DiaMedica Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: DiaMedica Therapeutics Posts Qtrly Loss Per Share $0.17
DiaMedica Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview
DiaMedica Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Ceridian HCM Holding, Norwegian Cruise Line Holdings, Royal Caribbean Group
Brief: Diamedica Therapeutics Announces Positive Interim Results From Phase 2 Redux Study In Ckd
Brief: DiaMedica Therapeutics Announces FDA Clearance Of IND Application To Initiate Phase 2/3 Clinical Trial For Dm199 For Acute Ischemic Stroke
DiaMedica Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Diamedica Therapeutics Provides A Business Update And Announces First Quarter 2021 Financial Results
U.S. RESEARCH ROUNDUP-Endo International, Lennar, Uber Technologies
Brief: Diamedica Therapeutics Inc Says Cash Runway Through Mid-2022